Fig. 9: In vivo experiment of betulin combined with docetaxel in the treatment of PC3 prostate cancer subcutaneous xenograft tumor model.
From: SREBF1-based metabolic reprogramming in prostate cancer promotes tumor ferroptosis resistance
A Schematic of experimental design and procedure (n = 5). B Image of the tumor after treatment. C Body weight change curve of mice during the treatment process. D Tumor size change curve during treatment. E Tumor weight after treatment completion. F Results of the variance analysis of the factorial design for treatment effects. G Oil red O staining of tumor tissue after treatment. H Quantification of Oil Red O staining. I Ki-67 staining of tumor tissue after treatment. J Quantification of Ki-67 staining. i.p. intraperitoneal Injections, SC subcutaneous. Data were presented as mean ± SD. (ns, P ≥ 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001).
